

Date: 27th December, 2024

To,

Corporate Relationship Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, **Mumbai-400 001**

Dear Sir/Madam,

Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.

Ref: Stock Code: NSE: SHILPAMED/BSE-530549

Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor, Plot No.C/1, G Block Bandra Kurla Complex, Bandra (E) **MUMBAI-400 051**

Eurasia (EAEU) GMP Approval of Shilpa Medicare Ltd. Unit IV, Jadcherla, Telangana and Unit VII, Nacharam, Hyderabad, Telangana.

This is to inform you that Shilpa Medicare Limited, Unit IV, Jadcherla, Telangana, India and Shilpa Medicare Ltd, Unit VII, Nacharam, Hyderabad, Telangana, India had undergone a GMP inspection by Ministry of Health, Belarus for GMP certification from the Eurasian Economic Union in October 2024.

Both units of Shilpa Medicare Ltd (Unit IV and Unit VII), have now received GMP approval of Eurasia, the member countries for which are Belarus, Russia, Kazakhstan, Kyrgyzstan and Armenia.

This approval will open up significant business opportunities in these countries.

Unit IV of Shilpa Medicare Lid. is engaged in the manufacture, testing, release and distribution of sterile Injectable and non-sterile Oral finished dosage forms in the US, Europe and rest of the world markets.

Unit VII of Shilpa Medicare Ltd. is engaged in testing raw materials, packing materials, finished dosage forms and other testing activities.

About Shilpa:

Shilpa is an integrated pharmaceutical group with business interests in niche Oncology & Non-oncology APIs, Peptides, Polymers, differentiated finished dosage formulations including orally dispersible films & transdermal patches along with carefully crafted biological portfolio. Shilpa also provides end-to-end CDMO services to global pharmaceutical companies across all its business segments based on its strong R&D and manufacturing capabilities backed by four R&D units and seven manufacturing facilities.

With Regards,

For SHILPA MEDICARE LIMITED

Ritu Tiwary Company Secretary & Compliance Officer